How to choose the right treatment guide
Your diagnosis determines which Lutetium therapy may be relevant for you. Use this quick chooser:
- You or your loved one has prostate cancer that has spread and is no longer responding to hormone therapy → Read about Lu-177 PSMA therapy
- You or your loved one has a neuroendocrine tumor of the gut, pancreas, or lung → Read about Lu-177 DOTATATE therapy
- You're researching cutting-edge options for a less common cancer → Read about emerging therapies
- You're not sure where to start → Start with “What is Lutetium Therapy?”
What all Lu-177 therapies have in common
Despite targeting completely different cancers, all currently-available Lutetium therapies share the same fundamental approach:
- A small targeting molecule that recognizes a surface marker on cancer cells
- Attached to a radioactive Lu-177 atom delivering short-range radiation
- Given as an outpatient IV infusion
- Repeated in cycles, typically every 6–8 weeks
- Preceded by a diagnostic scan that confirms the target is present
- Causes far milder side effects than traditional chemotherapy
The growing future of theranostics
Lutetium therapy is part of a broader medical field called theranostics— combining diagnostics and therapy. As researchers discover more cancer-specific surface markers, new theranostic drugs are emerging:
- Lu-177 FAP — targets fibroblast activation protein, found in many solid tumors (pancreatic, sarcoma, breast)
- Lu-177 PSMA for earlier prostate cancer — moving the therapy earlier in disease
- Actinium-225 PSMA — stronger alpha-emitting variant for Lu-177 PSMA therapy non-responders
- Lu-177 for pediatric neuroblastoma — early-stage trials